HomeCompareRSLBF vs PLD

RSLBF vs PLD: Dividend Comparison 2026

RSLBF yields 1.37% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $6.48M in total portfolio value
10 years
RSLBF
RSLBF
● Live price
1.37%
Share price
$23.00
Annual div
$0.31
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.6K
Annual income
$149.57
Full RSLBF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — RSLBF vs PLD

📍 PLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRSLBFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RSLBF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RSLBF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RSLBF
Annual income on $10K today (after 15% tax)
$116.34/yr
After 10yr DRIP, annual income (after tax)
$127.13/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $4,467,843.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RSLBF + PLD for your $10,000?

RSLBF: 50%PLD: 50%
100% PLD50/50100% RSLBF
Portfolio after 10yr
$3.26M
Annual income
$2,628,292.87/yr
Blended yield
80.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

RSLBF
No analyst data
Altman Z
6.1
Piotroski
7/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RSLBF buys
0
PLD buys
0
No recent congressional trades found for RSLBF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRSLBFPLD
Forward yield1.37%3.18%
Annual dividend / share$0.31$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$21.6K$6.50M
Annual income after 10y$149.57$5,256,436.18
Total dividends collected$1.4K$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: RSLBF vs PLD ($10,000, DRIP)

YearRSLBF PortfolioRSLBF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$10,837$136.87$11,255$555.24$418.00PLD
2$11,734$138.62$13,062$1,018.59$1.3KPLD
3$12,696$140.28$15,903$1,926.67$3.2KPLD
4$13,726$141.84$20,839$3,823.32$7.1KPLD
5$14,830$143.33$30,464$8,166.08$15.6KPLD
6$16,013$144.72$52,054$19,457.30$36.0KPLD
7$17,280$146.04$109,886$54,188.93$92.6KPLD
8$18,637$147.29$304,030$186,451.18$285.4KPLD
9$20,090$148.46$1,166,125$840,813.32$1.15MPLD
10$21,646$149.57$6,504,190$5,256,436.18$6.48MPLD

RSLBF vs PLD: Complete Analysis 2026

RSLBFStock

RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment worldwide. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, OAR dose reduction, robustness, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information system to support cancer treatment activities. In addition, it offers RayCommand, a treatment control system that is compatible with various hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights. Further, the company provides training courses related to its products. RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden.

Full RSLBF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this RSLBF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RSLBF vs SCHDRSLBF vs JEPIRSLBF vs ORSLBF vs KORSLBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.